Hépato-Gastro & Oncologie Digestive
MENUFOLFOXIRI panitumumab in TRIPLETE study, more is not better Volume 30, issue 2, February 2023
Author
Normandie Univ, UNIROUEN, Inserm 1245, IRON group, Hôpital Universitaire de Rouen, service d’Hépato-Gastroentérologie, 76000 Rouen
* Correspondance : D. Sefrioui
- DOI : 10.1684/hpg.2023.2532
- Page(s) : 251-5
- Published in: 2023
Référence :Rossini D, Antoniotti C, Lonardi S, et al. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GO. J Clin Oncol 2022 ; 40 : 2878-2888IntroductionL’utilisation d’anticorps anti-EGFR en association au doublet FOLFIRI ou FOLFOX constitue un standard pour le traitement de première ligne (L1) [...]